Many investors may be looking to track stock price momentum by looking at different historical information. Akebia Therapeutics, Inc. (NASDAQ:AKBA) currently has a 6 month price index of 1.40000. The six month price index is simply measured by dividing the current share price by the share price six months ago. A ratio above one indicates an increase in share price over the six month period. A ratio below one indicates that the price has decreased over that specific period.
Traders might also be keeping an eye on the Piotroski Score or F-Score. The score is named after its developer Joseph Piotroski who created a ranking scale from 0-9 to help determine the financial strength of a company. Akebia Therapeutics, Inc. (NASDAQ:AKBA) currently has a Piotroski Score of 1. To arrive at this score, Piotroski gave one point for every piece of criteria met out of the nine considered. In terms of profitability, one point was given if there was a positive return on assets in the current year, one point if operating cash flow was positive in the current year, one point for higher ROA in the current period compared to ROA for the previous year, and one point for cash flow from operations greater than ROA. In terms of leverage and liquidity, one point was given for a lower ratio of long term debt in the current period compared to the previous year, one point was given for higher current ratio compared to the previous year, and one point if no new shares were issued in the last year. In terms of operating efficiency, one point was given for higher gross margin compared to the previous year, and one point was given for a higher asset turnover ratio compared to the previous year. In general, a stock with a score of 8 or 9 would be considered strong while a stock with a score from 0-2 would be considered weak.
Investors may also be watching company stock volatility data. Akebia Therapeutics, Inc. (NASDAQ:AKBA)’s 12 month volatility is presently 63.267300. The 6 month volatility is 46.474400, and the 3 month is noted at 51.794900. Stock price volatility may be used to identify changes in market trends. When markets become very volatile, this may point to a change in investor sentiment. Watching volatility in combination with other technical indicators may help investors discover important trading information.
Diving in a bit further, we can take a quick look at the Q.i. (Liquidity) Value. Akebia Therapeutics, Inc. (NASDAQ:AKBA) has a present Q.i. value of 90.00000. This value ranks stocks using EBITDA yield, FCF yield, earnings yield and liquidity ratios. The Q.i. value may help spot companies that are undervalued. A larger value would represent low turnover and a higher chance of shares being mispriced. A lower value may indicate larger traded value meaning more sell-side analysts may cover the company leading to a smaller chance shares are priced improperly.
Investors keeping an eye on shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) may be examining the company’s FCF or Free Cash Flow. FCF is a measure of the financial performance of a company. FCF is calculated by subtracting capital expenditures from operating cash flow. Currently, Akebia Therapeutics, Inc. (NASDAQ:AKBA) has an FCF score of 0.460091. The FCF score is an indicator that is calculated by combining free cash flow stability with free cash flow growth. Typically, a higher FCF score value would indicate high free cash flow growth. The company currently has an FCF quality score of -4.279348. The free quality score helps estimate free cash flow stability. FCF quality is calculated as the 12 ltm cash flow per share over the average of the cash flow numbers. With this score, it is generally considered that the lower the ratio, the better.